The aim of the present study was to evaluate effects of long-term treatment with rilmenidine compared with atenolol on lipid and glucose metabolism and cardiovascular remodelling in hypertension. In total, 37 patients with hypertension were randomised to rilmenidine 1-2 mg/day or atenolol 50-100 mg/day for 26 weeks. Standard oral glucose tolerance test with a parallel measurement of insulin and glucose levels was performed. The 'areas under the curve' (AUC) for insulin and glucose were calculated. Plasma lipids, left ventricular mass index (LVMI), and intima-media thickness (IMT) were measured. Brachial artery diameter during reactive hyperaemia was used to test endotheliumdependent vasodilatation (EDVD). Blood pressure reduction was equally achieved in both treatment arms. The fasting glucose level increased in the atenolol group from 4.870.6 to 5.270.7 mmol/l (Po0.01). The AUC of glucose in rilmenidine group decreased from 860793 to 737766 mmol/min/l (Po0.05), and in the atenolol group it increased from 937786 to 989788 mmol/min/l (Po0.05). Rilmenidine showed a positive effect on lipid levels, whereas in the atenolol group a significant decrease of high-density lipoprotein cholesterol was observed. Left ventricular mass index decreased with rilmenidine by 9.6% and by 6.9% with atenolol (Po0.05). Intima-media thickness significantly decreased in the rilmenidine group. Endothelium-dependent vasodilatation slightly increased on in the rilmenidine group, while on in the atenolol group it remained unchanged. Our data suggest that in hypertensive patients central inhibition of sympathetic drive can produce favourable effects on glucose and lipid metabolism compared with standard b-blockade with a similar antihypertensive efficacy. Rilmenidine also provides beneficial effects on cardiovascular remodelling and altered endothelial function in hypertension.
Introduction
The metabolic effects of antihypertensive drugs still remain the key aspect of the management of metabolic syndrome and a point of debate concerning the 'first-choice' drugs in hypertension treatment. Although the outcome benefits of ACE inhibitors and ATII receptor antagonists in diabetic patients are well established, 1,2 the first-line therapy of the metabolic syndrome remains controversial. Theoretical background and clinical data exist in favour of using selective agonists of I 1 -imidazoline receptors in such patients. 3, 4 As sympathetic activation plays an important role in the genesis of insulin resistance and its complications, decrease in such overactivity should be considered a correct way to improve the whole conglomerate of metabolic abnormalities following insulin resistance syndrome, including lipid disturbances. Using b-blocking agents one can only eliminate peripheral effects of sympathetic overdrive and even worsen the metabolic state owing to vascular receptor blockade. This can result in decrease of glucose tolerance, increase in triglyceride levels and decrease in highdensity lipoprotein (HDL) levels, as well as weight gain. 5, 6 Recently, the clinical relevance of these negative metabolic effects has been documented as an increased risk of diabetes mellitus, 7 which is also true for chlorthalidone. 8 Alternatively, the positive effects on glucose and lipid metabolism of centrally acting drugs -agonists of imidazoline receptors were shown. 9 Although the long-term outcome of negative metabolic effects of the antihypertensive drugs is unknown, as well as the possible prognostic benefits of the I 1 -imidazoline receptor agonists have not being established, further research in the field of clinical evaluation of such effects is needed. The future of hypertension management lies in the implementation of therapy, affecting the underlying mechanisms of the disease progression with a concomitant correction of all risk factors, including hyperglycaemia, hyperinsulinaemia, and dyslipidaemia.
Prevention and treatment of target-organ damage, including surrogate end points such as left ventricular hypertrophy (LVH), intima-media thickness (IMT), and endothelial function (EF) can be also considered the major goal of antihypertensive therapy. The positive prognostic value of LVH regression and carotid IMT decrease is well documented, [10] [11] [12] [13] [14] [15] whereas the independent prognostic significance of endothelial dysfunction is now actively studied. 16 The data of major clinical trials and meta-analyses indicate that angiotensin II receptor antagonists and ACE inhibitors are more effective in correction of LVH and EF compared with other drug classes, [17] [18] [19] [20] [21] [22] while calcium antagonists can reverse carotid atherosclerosis. [23] [24] [25] All the same, the relatively newer drug class of I 1 -imidazoline receptor agonists was not included in the majority of meta-analyses and is less studied in the field of both hard and intermediate end point prevention. Besides, the existing clinical data show a beneficial potential of these agents to decrease LVH. 26, 27 Sympathetic overactivity plays an important role in cardiovascular remodelling, and decrease in central sympathetic stimulation can be beneficial in its correction. Proof awaits the demonstration of the effects of I I receptor agonists on EF and IMT.
The aim of the present study was to evaluate the effects of long-term treatment with rilmenidine compared with atenolol on lipid and glucose metabolism and cardiovascular remodelling in hypertensive patients.
Methods

Study participants and design
The patients for the study were selected from the outpatient clinic in primary health care in one of the city districts of St Petersburg. Patients were recruited for the study during their annual checkup at the outpatient clinic. All patients had a previously established diagnosis of essential hypertension (at least for 1 year) based on the standard ESH criteria.
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The possible causes of secondary hypertension were excluded (no clinical signs, normal results of serum urea, creatinine, and electrolytes, normal urinary excretion of catecholamines, and normal renal imaging studies, including radionuclide renogram and/or intravenous urography and/or ultrasound scan). All participants were white, aged from 18 to 55 years, and had no concomitant cardiovascular diseases and/or diabetes. Only patients without regular medication during last 6 months were included. Patients were considered eligible for inclusion if they had mean blood pressure in the range 140/90-180/110 mm Hg.
In total, 37 eligible patients (16 males and 21 females) were randomised to rilmenidine (EGIS AO) 1 mg/day or atenolol (AstraZeneca, UK) 50 mg/day and treated for 26 weeks. The study was performed in an open-label design. The visits were scheduled on weeks 4, 12, and 26. After 4 weeks of treatment the study medications were titrated up to 2 and 100 mg/day, respectively. No special diet or other lifestyle modifications were recommended. During the first and final (26th week) visits, patients were examined according to the protocol that included vital signs (blood pressure and heart rate), recordings (in the morning, without medication), registration of weight, height, and body mass index (BMI). Ambulatory blood pressure monitoring (ABPM), oral glucose tolerance test (OGTT) and lipid level measurement, ultrasound examinations were performed at baseline within 1 week before randomisation and after the 26th week of treatment. All investigators, performing ultrasound measurements and biochemistry were blinded concerning study medication and visit schedule.
The study protocol was approved by the local Ethics Committee and informed consent was obtained from all the participants.
Ambulatory blood pressure measurements Ambulatory blood pressure monitoring was performed for 24 h using SpaceLabs 90207 (SpaceLabs Inc., Redmond Washington, USA) ambulatory blood pressure monitor, which has been validated for accuracy. 29 The monitor was applied to the nondominant arm between 0900 and 1200 hours, and the patient was instructed to carry the arm as normal between measurements but to rest the arm at heart level during measurements. The monitor was programmed to measure blood pressure at 15-min intervals during the daytime and 30-min intervals throughout the night. The monitor was removed the following day and the data were transferred into a personal computer (DABL software package). The 24-h, daytime and nighttime systolic, diastolic, and mean blood pressure were calculated. The day and night hours were considered individually according to the patient's daily schedule. Erroneous measurements identified during the data editing were removed from the recording.
Oral glucose tolerance test Standard OGTT (75 g of glucose) with a parallel measurement of fasting, 30, 60, 90, and 120 min insulin and glucose levels was performed at screening and at the end of treatment. Glucose concentrations were measured with Cobas Integra (Roche, Switzerland). Insulin was measured by radioimmunoassay using specific antibody 'Labodia' (Switzerland).
The 'areas under the curve' (AUC) for insulin and glucose were calculated according to H Seltzer et al.'s formula. 30 AUCg
where AUCg area under the curve of glucose, G 0 -fasting glucose, G 30 -glucose on 30 min of OGTT, G 60 -60-min glucose level, G 90 -90-min level, G 120 -2-h glucose level.
where AUCins -area under the curve of insulin, I 0 -fasting insulin, I 30 -insulin on 30 min of OGTT, I 60 -60-min level, I 90 -90-min level, I 120 -2 h insulin level.
The index of insulin resistance was calculated as fasting serum insulin to plasma glucose ratio.
Lipid measurements
Total plasma cholesterol, low-density lipoprotein (LDL)-cholesterol, HDL-cholesterol, and triglycerides were determined twice in all patients. Total plasma cholesterol and triglycerides were determined enzymatically. High-density lipoproteincholesterol was measured after precipitation of apolipoprotein B-containing lipoproteins in whole plasma by heparin-anganese chloride. Very-lowdensity lipoprotein (VLDL)-cholesterol was assumed to equal one-fifth of plasma triglyceride level, and LDL cholesterol was determined by difference according to the method of Friedewald et al. 31 The atherogenic coefficient was calculated as the ratio of (total cholesterolÀHDL-cholesterol) to LDL-cholesterol.
Echocardiography. Echocardiography was performed in M-and 2D-mode with a Vingmed-CFM-800 machine (GE, USA) using a 3.25 MHz transducer. Echocardiographic studies of good quality were performed in the morning with the subject in supine left lateral decubitus, after 30 min of rest.
The interventricular septum and left ventricular posterior wall were chosen in the parasternal long axis view. All measurements were made according to the Penn convention. The left ventricular mass was calculated by the Devereux and Reicheck formula. 32 The left ventricular mass index (LVMI) was obtained by dividing LVM on body surface area (BSA), calculated by the formula of Dubois and Dubois. 33 Left ventricular hypertrophy was diagnosed by indexation to BSA using the following criteria: when LVMI was greater than 134 g/m 2 in men and 110 g/m 2 in women. 34 Patients with regional wall movement abnormalities and depressed systolic function (EF less than 50%) were excluded from the study. Control echocardiography study was performed by the same observer. (r ¼ 0.94, Po0.01 for the intraobserver variability of LVMI measurements).
Doppler measurements. Transmitral flow was assessed by continuous-wave Doppler with the measurement of early peak velocity (E), atrial peak velocity (A) and their relation (E\A). Isovolumetric relaxation time (IVRT) was also determined. The flow in pulmonary veins was analysed in order to distinguish different patterns of relaxation abnormalities.
Ultrasound measurements of intima-media thickness
The examination was performed by the same observer (r ¼ 0.91, Po0.05) with a patient in a lying position with a slight deviation of the head to the opposite side of the tested artery. High-resolution ultrasound with a 7 MHz transducer was used (Vingmed CFM 800 machine). The measurements of IMT were assessed according to a standard technique on three levels and bilaterally -on proximal, medial and distal points in the posterior wall of the main carotid artery 1 cm from the bifurcation. The measurements were obtained at the end of diastole. The IMT was detected as a destination from first (tunica intima) and second (tunica adventicia) echo lines of the vessel according to Pignoli et al. 35 and Salonen et al. 36 The mean value from 12 taken measurements was calculated. Previous studies showed good reproducibility of the method is up to 95%. 37 Endothelial function study Brachial artery vasodilator responses were measured in the dominant arm according to the standard technique.
38,39 A 10-MHz linear ultrasound transducer attached to a Vingmed CFM-800 ultrasound machine used to image the brachial artery longitudinally just above the antecubital fossa. All measurements were performed by a single observer, and intraobserver variability in our laboratory for the repeated measurements was acceptable (r ¼ 0.92, Po0.01). After basal measurements of brachial artery diameter were recorded, a blood pressure cuff was inflated on the proximal portion of the arm up to 200 mm Hg for 5 min, creating distal limb ischaemia. After release of the cuff, reactive hyperaemia occurs and flow in the brachial artery increases. The image of the artery was taken during the first 2 min of the reactive hyperaemia (after 60 s). The flow-mediated dilator response (a ratio of the delta of 60 s. diameter and baseline one to baseline measurement, presenter in percentage) was as used as a measure of endothelium-dependent vasodilatation.
Statistical methods
Comparison between two treatment groups was performed by two-way ANCOVA. All tests were two-sided. A P-value o0.05 was considered statistically significant. All calculated P-values were interpreted exploratively for the hypothesis generated only.
Results
All patients enrolled successfully completed the study according to the protocol. The baseline clinical data for the treatment arms are shown in Table 1 . The mean patient age was 4974 years, mean BMI was 3174 kg/m 2 . The proportion of male/ female subjects was similar (8/10 in rilmenidine group and 8/11 in atenolol). The groups were well matched for age, blood pressure, BMI, and haemodynamic parameters. On week 4, the dose of the drug was uptitrated in 13 patients in rilmenidine group and in 15 patients in atenolol group (no statistically significant difference between the groups). 'Office' blood pressure changed from 165710/10076 mm Hg to 159711/9677 on week 4 visit, 14978/9277 on week 12 visit and 14378/ 8776 mm Hg on week 26 (Po0.01 vs baseline level for all visits) in the rilmenidine group and from 166711/10177 mm Hg to 154711/9476, 144710/ 8877, and 14079/8277 mm Hg, respectively, in the atenolol group (Po0.05 for week 4 vs baseline, Po0.001 for weeks 12 and 26 vs baseline). The 'office' blood pressure was normalised in 13 patients in the atenolol group and in 12 patients in the rilmenidine group (NS). Patients taking rilmenidine experienced few side effects (one patient -headache and one patient dry mouth), while five patients in the atenolol group experienced mild side effects (abdominal pain, moderate bradycardia (two cases), weakness, sleep disturbances) slightly more frequent (NS), no adverse effects resulted in interruption and/or discontinuation of the study drugs.
Ambulatory blood pressure monitoring
The antihypertensive efficacy of both drugs in the studied drugs was comparable ( Table 2) . Rilmenidine produced a slightly higher reduction of 24-h diastolic blood pressure (DBP), but these discrepancies were not statistically significant. In both groups the antihypertensive effect was observed during the daytime and nighttime. The diurnal index did not change significantly in any group. Atenolol showed Abbreviations: BP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; MBP, mean blood pressure. *Po0.05 compared with baseline levels. **Po0.01 compared with baseline level.
How can we block sympathetic overactivity? AO Konrady et al a negative cardiochronotrophic effect, while rilmenidine did not change heart rate significantly (Po0.01 for atenolol vs rilmenidine).
Oral glucose tolerance test
The results of glucose and insulin measurements during OGTT are shown in Table 3 . Fasting glucose levels in the rilmenidine group were stable, and in the atenolol group increased from 4.870.6 mmol/l to 5.270.7 mmol/l (Po0.01). The glucose levels on discrete points of the test changed insignificantly. Only the glucose level at 60 min in patients taking rilmenidine decreased from 7.870.6 mmol/l to 7.470.5 mmol/l (Po0.05) with a parallel decrease in insulin level (NS). Fasting insulin level decreased significantly only in rilmenidine group. Alternatively, atenolol increased the index of insulin resistance (Po0.05).
Lipids Table 4 shows the changes in plasma lipid levels during the study. Total cholesterol level remained unchanged in both groups, but the level of different lipoproteins and triglycerides significantly changed. Treatment with rilmenidine resulted in complex positive changes in lipid profile -decrease in LDL, increase in HDL level, decrease in VLDL-cholesterol and triglycerides. Therapy with a b-blocking agent resulted in a slight increase in VLDL-cholesterol and decrease in HDL level, which was accompanied by an increase in atherogenic coefficient (Po0.01 between the groups).
Echocardiography
Parameters of echocardiography at baseline and after 26 weeks of treatment are presented in Table 5 . The interventricular wall thickness changed only in the rilmenidine group (Po0.05), posterior wall thickness and left ventricular diastolic dimension did not change significantly. Besides, LVMI decreased from 11479 to 10378 on rilmenidine (9.6%, Po0.01) and slightly decreased on atenolol (from 11579 to 10779, 4.6%, NS). Parameters of diastolic function remained unchanged in both groups, with a tendency of IVRT to decrease. 
Vascular ultrasound
Dynamics of IMT measurements is presented in Figure 1 . The decrease in IMT was observed only in patients taking rilmenidine. In the group treated with atenolol there were no changes in IMT.
Results of the measurements of EDVD are shown in Figures 2 and 3 . The diameter of the brachial artery slightly increased in both groups, but was not statistically significant. Endothelium-dependent vasodilatation was altered at baseline in both groups. After treatment, the percent of EDVD increased only in the rilmenidine group (Po0.05 between the groups). At baseline 14 patients in the rilmenidine group and 13 in the atenolol group had insufficient EDVD (less than 10%) and four patients, respectively, having paradox vasoconstriction. After treatment with rilmenidine five patients regained a 'normal' response to reactive hyperaemia (more than 10% of increase in vascular diameter), whereas in the atenolol group no patients with such an effect were observed.
Discussion
The present study addresses the metabolic and target-organ protecting effects of newly implemented drugs in hypertension management. Owing to development of selective I 1 -imidazoline agonists, the last decade has seen what has been called the renaissance of centrally acting drugs. 40 The exact role of this drug class remains poorly understood, but appears to be becoming more important and will probably be more widely used in the future.
First of all, the study documented a comparable blood pressure lowering effect of rilmenidine to that of atenolol, a gold standard in hypertension treatment, according to both office and ABPM blood pressure measurements. The same results of such a comparison had already been obtained in a shorter duration study. 41 At the same time, atenolol significantly reduced heart rate, whereas in the rilmenidine group no reduction of HR was observed. This can indicate that the major haemodynamic effect of the latter is reduction of vascular resistance. It is worth mentioning the better tolerability of rilmenidine, although the small study size does not allow documenting it statistically. The overall good tolerability of rilmenidine had been previously confirmed in larger trials. 42, 43 Next, the study showed several positive metabolic effects of rilmenidine compared with atenolol, including decrease of hyperinsulinaemia, hyperglycaemia, hypertriglycaeridemia and other factors contributing to metabolic syndrome. Besides, these changes were observed in an unselected patient population and do not definitely have prognostic implications, they could indicate that use of rilmenidine can be favourable in correction of risk factors other than hypertension and possibly prevent diabetes development or delay its manifestation in predisposed patients. The positive metabolic effects of rilmenidine had been already shown in comparison with amlodipine and captopril. 9, 44 Thus, even compared to more metabolically neutral drugs such as calcium antagonists and ACE inhibitors, rilmenidine has shown advantages concerning metabolic action. These data, as well as findings of the present study, may be interpreted as evidence for the necessity of primary use of centrally acting drugs in patient with metabolic disorders. Sympathetic overactivity, frequently observed in patients with obesity, hypertension and insulin resistance, can be considered as a special indication for selective I 1 -imidazoline agonists as an antihypertensive agent. The comparable effect of rilmenidine to lisinopril detected by ABPM was recently confirmed in another study in patients with metabolic syndrome. 45 The latter recent study documented comparable metabolic profile of rilmenidine compared to ACE inhibitor, considered to be the leading class in treatment of patients with metabolic abnormalities. Other representative of selective I 1 -imidazoline agonists moxonidine has been also tested for its possible metabolic activity and some favourable results were obtained. 46 Finally, the present study provides the data concerning effects of rilmenidine on cardiovascular remodelling. As to left ventricular hypertrophy, previous studies documented reduction of LVMI up to 16% 44 or even 18.6% 47 in patients treated with rilmenidine for 1 year. Data are lacking concerning such effect of alternative agent moxonidine. In our study a reduction in 9.6% in 26-week period was achieved, which was significantly higher than in the atenolol group. This effect was observed at the same level of blood pressure changes that can indicate the participation of nonhaemodynamic mechanisms of antihypertrophic effect of rilmenidine. The limitation of the study concerning regression of LVH and IMT was the rather short duration, as 1 year appears to be optimal time to test antihypertrophic effects of drugs. 48 At the same time, significant regression of LVH over 6 months seems to be convincing concerning the positive effect of rilmenidine on cardiac and vascular remodelling, while the extent of this effect can be tested in future larger trials. The data on IMT reduction appear to be of primary importance because of the scarcity of relevant information in the literature. The data obtained can be explained by additional benefit of blocking sympathetic overactivity as decrease of hypertrophy caused by sympathetic overstimulation. One can speculate that discrepancies between effects of central and peripheral sympathetic blockade can be explained by participation in cardiac and vascular hypertrophy both b-1 and a-1 receptormediated mechanisms, 49, 50 but this was not under consideration in the present study. Another explanation lies in the field of interactions of sympathetic activity, LVH and insulin level. 51 The revealed discrepancies concerning effects on EF are easier to interpret. b-Blockers are known to have unfavourable effects on EDVD, 52 while improvement in EF in the rilmenidine group can be explained by a direct decrease in sympathetic stimulation and positive metabolic changes contributing to the functioning of the vascular endothelium. Endothelial dysfunction is considered nowadays an independent negative risk factor, 16 and documenting positive effects in EDVD can serve as additional evidence for rilmenidine benefits in hypertension management. Additionally, although the long-term cardiovascular consequences of such deleterious effects remain unclear, a recent metaanalysis evidenced an increasing cardiovascular mortality with atenolol compared with other antihypertensive classes. 53 In conclusion, the data obtained suggest that in hypertensive patients central inhibition of sympathetic drive can produce favourable effects on glucose and lipid metabolism compared with standard b-blockade with a similar antihypertensive efficacy. Moreover, rilmenidine, compared with atenolol, provides beneficial effects on cardiovascular remodelling and altered EF in hypertension and, therefore, protects against target-organ damage beyond blood pressure reduction.
This indicates that I 1 -imidazoline agonist rilmenidine can be prescribed in a large proportion of hypertensive patients with additional risk factors and/or target-organ damage.
